Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

被引：0

作者：

Gustavo H. Kijak

Bahar Ahani

Douglas Arbetter

Fernando Chuecos

Vancheswaran Gopalakrishnan

Jagadish Beloor

Tyler Brady

Amy Nguyen

Tiffany L. Roe

Nicolette Schuko

Tianhui Zhang

F. D. Richard Hobbs

Francisco Padilla

Elizabeth J. Kelly

Hugh Montgomery

Katie Streicher

机构：

[1] BioPharmaceuticals R&D,Translational Medicine, Vaccines & Immune Therapies

[2] AstraZeneca,Formerly Data Sciences and Quantitative Biology

[3] Bioinformatics,Nuffield Department of Primary Care Health Sciences

[4] Vaccines & Immune Therapies,Formerly Translational Medicine, Vaccines & Immune Therapies

[5] BioPharmaceuticals R&D,Department of Medicine

[6] AstraZeneca,undefined

[7] Biometrics,undefined

[8] Vaccines & Immune Therapies,undefined

[9] BioPharmaceuticals R&D,undefined

[10] AstraZeneca,undefined

[11] Biometrics,undefined

[12] Vaccines & Immune Therapies,undefined

[13] BioPharmaceuticals R&D,undefined

[14] AstraZeneca,undefined

[15] BioPharmaceuticals R&D,undefined

[16] AstraZeneca,undefined

[17] University of Oxford,undefined

[18] Centro de Investigación en Cardiología y Metabolismo,undefined

[19] BioPharmaceuticals R&D,undefined

[20] AstraZeneca,undefined

[21] University College London,undefined

来源：

Infectious Diseases and Therapy | 2023年 / 12卷

关键词：

AZD7442; Cilgavimab; COVID-19; Tixagevimab; Treatment-emergent viral variants;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2691 / 2707

页数：16

共 50 条

[41] Temporal Analysis of SARS-CoV-2 Variants during the COVID-19 Pandemic in Nepal
Paudel, Samrat
Dahal, Amol
Bhattarai, Hitesh Kumar
COVID, 2021, 1 (02): : 423 - 434
[42] Covid-19 convalescent plasma and SARS-CoV-2 viral variants
Joob, B.
Wiwanitkit, V.
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2021, 28 (03) : 306 - 306
[43] Spatiotemporal prevalence of COVID-19 and SARS-CoV-2 variants in Africa
Gao, Li-Ping
Zheng, Can-Jun
Tian, Ting-Ting
Brima Tia, Alie
Abdulai, Michael K.
Xiao, Kang
Chen, Cao
Liang, Dong-Lin
Shi, Qi
Liu, Zhi-Guo
Dong, Xiao-Ping
FRONTIERS IN PUBLIC HEALTH, 2025, 13
[44] Models for COVID-19 Early Cardiac Pathology Following SARS-CoV-2 Infection
Fremont-Smith, Maurice
Gherlone, Nicole
Smith, Nora
Tisdall, Philip
Ricke, Darrell O.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 113 : 331 - 335
[45] Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine Response
Braitsch, Krischan
Jeske, Samuel D.
Stroh, Jacob
Hefter, Maike
Platen, Louise
Bachmann, Quirin
Renders, Lutz
Protzer, Ulrike
Goetze, Katharina S.
Herhaus, Peter
Verbeek, Mareike
Spinner, Christoph D.
Bassermann, Florian
Hoegner, Marion
Haller, Bernhard
Schneider, Jochen
Heider, Michael
VACCINES, 2024, 12 (08)
[46] Exploring nanoselenium to tackle mutated SARS-CoV-2 for efficient COVID-19 management
Singh, Avtar
Singh, Paramjit
Kumar, Rajeev
Kaushik, Ajeet
FRONTIERS IN NANOTECHNOLOGY, 2022, 4
[47] Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2
Shah, Syed Muhammad Ali
Rasheed, Tahir
Rizwan, Komal
Bilal, Muhammad
Iqbal, Hafiz M. N.
Rasool, Nasir
Toma, Sebastian
Marceanu, Luigi Geo
Bobescu, Elena
JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (03) : 331 - 346
[48] Understanding Molecular Actors of SARS-CoV-2 Virulence to Tackle COVID-19 Outbreak
Berisio, Rita
CELLS, 2022, 11 (22)
[49] Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
Gomez, Carmen Elena
Perdiguero, Beatriz
Esteban, Mariano
VACCINES, 2021, 9 (03) : 1 - 13
[50] Treatment of SARS-CoV-2(COVID-19): A safety perspective
Joshua Davis
Ugochukwu Umeh
Rand Saba
World Journal of Pharmacology, 2021, 10 (01) : 1 - 32

← 1 2 3 4 5 →